Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1998 May;77(10):1672–1676. doi: 10.1038/bjc.1998.275

High-dose therapy including carboplatin adjusted for renal function in patients with relapsed or refractory germ cell tumour: outcome and prognostic factors.

M P Lyttelton 1, E S Newlands 1, C Giles 1, M Bower 1, A Guimaraes 1, S O'Reilly 1, G J Rustin 1, D Samson 1, E J Kanfer 1
PMCID: PMC2150058  PMID: 9635847

Abstract

Thirty-one consecutive patients with relapsed or refractory GCT received an HDT schedule including carboplatin, the dose of which was adjusted to measured glomerular filtration rate. There was one HDT-associated death (3%), due to acute renal failure. The 3-year probability of overall and disease-free survival for 21 patients with primary refractory disease or responsive relapse was 60% and 42%, respectively, while none of ten patients with refractory relapse have survived disease free.

Full text

PDF
1675

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Barnett M. J., Coppin C. M., Murray N., Nevill T. J., Reece D. E., Klingemann H. G., Shepherd J. D., Nantel S. H., Sutherland H. J., Phillips G. L. High-dose chemotherapy and autologous bone marrow transplantation for patients with poor prognosis nonseminomatous germ cell tumours. Br J Cancer. 1993 Sep;68(3):594–598. doi: 10.1038/bjc.1993.392. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Beyer J., Kramar A., Mandanas R., Linkesch W., Greinix A., Droz J. P., Pico J. L., Diehl A., Bokemeyer C., Schmoll H. J. High-dose chemotherapy as salvage treatment in germ cell tumors: a multivariate analysis of prognostic variables. J Clin Oncol. 1996 Oct;14(10):2638–2645. doi: 10.1200/JCO.1996.14.10.2638. [DOI] [PubMed] [Google Scholar]
  3. Broun E. R., Nichols C. R., Kneebone P., Williams S. D., Loehrer P. J., Einhorn L. H., Tricot G. J. Long-term outcome of patients with relapsed and refractory germ cell tumors treated with high-dose chemotherapy and autologous bone marrow rescue. Ann Intern Med. 1992 Jul 15;117(2):124–128. doi: 10.7326/0003-4819-117-2-124. [DOI] [PubMed] [Google Scholar]
  4. Calvert A. H., Newell D. R., Gumbrell L. A., O'Reilly S., Burnell M., Boxall F. E., Siddik Z. H., Judson I. R., Gore M. E., Wiltshaw E. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol. 1989 Nov;7(11):1748–1756. doi: 10.1200/JCO.1989.7.11.1748. [DOI] [PubMed] [Google Scholar]
  5. Hitchins R. N., Newlands E. S., Smith D. B., Begent R. H., Rustin G. J., Bagshawe K. D. Long-term outcome in patients with germ cell tumours treated with POMB/ACE chemotherapy: comparison of commonly used classification systems of good and poor prognosis. Br J Cancer. 1989 Feb;59(2):236–242. doi: 10.1038/bjc.1989.48. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Margolin K., Doroshow J. H., Ahn C., Hamasaki V., Leong L., Morgan R., Raschko J., Shibata S., Somlo G., Tetef M. Treatment of germ cell cancer with two cycles of high-dose ifosfamide, carboplatin, and etoposide with autologous stem-cell support. J Clin Oncol. 1996 Oct;14(10):2631–2637. doi: 10.1200/JCO.1996.14.10.2631. [DOI] [PubMed] [Google Scholar]
  7. Mead G. M., Stenning S. P., Parkinson M. C., Horwich A., Fossa S. D., Wilkinson P. M., Kaye S. B., Newlands E. S., Cook P. A. The Second Medical Research Council study of prognostic factors in nonseminomatous germ cell tumors. Medical Research Council Testicular Tumour Working Party. J Clin Oncol. 1992 Jan;10(1):85–94. doi: 10.1200/JCO.1992.10.1.85. [DOI] [PubMed] [Google Scholar]
  8. Mencel P. J., Motzer R. J., Mazumdar M., Vlamis V., Bajorin D. F., Bosl G. J. Advanced seminoma: treatment results, survival, and prognostic factors in 142 patients. J Clin Oncol. 1994 Jan;12(1):120–126. doi: 10.1200/JCO.1994.12.1.120. [DOI] [PubMed] [Google Scholar]
  9. Motzer R. J., Bosl G. J. High-dose chemotherapy for resistant germ cell tumors: recent advances and future directions. J Natl Cancer Inst. 1992 Nov 18;84(22):1703–1709. doi: 10.1093/jnci/84.22.1703. [DOI] [PubMed] [Google Scholar]
  10. Motzer R. J., Geller N. L., Tan C. C., Herr H., Morse M., Fair W., Sheinfeld J., Sogani P., Russo P., Bosl G. J. Salvage chemotherapy for patients with germ cell tumors. The Memorial Sloan-Kettering Cancer Center experience (1979-1989). Cancer. 1991 Mar 1;67(5):1305–1310. doi: 10.1002/1097-0142(19910301)67:5<1305::aid-cncr2820670506>3.0.co;2-j. [DOI] [PubMed] [Google Scholar]
  11. Motzer R. J., Gulati S. C., Tong W. P., Menendez-Botet C., Lyn P., Mazumdar M., Vlamis V., Lin S., Bosl G. J. Phase I trial with pharmacokinetic analyses of high-dose carboplatin, etoposide, and cyclophosphamide with autologous bone marrow transplantation in patients with refractory germ cell tumors. Cancer Res. 1993 Aug 15;53(16):3730–3735. [PubMed] [Google Scholar]
  12. Nichols C. R., Andersen J., Lazarus H. M., Fisher H., Greer J., Stadtmauer E. A., Loehrer P. J., Trump D. L. High-dose carboplatin and etoposide with autologous bone marrow transplantation in refractory germ cell cancer: an Eastern Cooperative Oncology Group protocol. J Clin Oncol. 1992 Apr;10(4):558–563. doi: 10.1200/JCO.1992.10.4.558. [DOI] [PubMed] [Google Scholar]
  13. Rosti G., Albertazzi L., Salvioni R., Pizzocaro G., Cetto G. L., Bassetto M. A., Marangolo M. High-dose chemotherapy supported with autologous bone marrow transplantation (ABMT) in germ cell tumors: a phase two study. Ann Oncol. 1992 Dec;3(10):809–812. doi: 10.1093/oxfordjournals.annonc.a058100. [DOI] [PubMed] [Google Scholar]
  14. Siegert W., Beyer J., Strohscheer I., Baurmann H., Oettle H., Zingsem J., Zimmermann R., Bokemeyer C., Schmoll H. J., Huhn D. High-dose treatment with carboplatin, etoposide, and ifosfamide followed by autologous stem-cell transplantation in relapsed or refractory germ cell cancer: a phase I/II study. The German Testicular Cancer Cooperative Study Group. J Clin Oncol. 1994 Jun;12(6):1223–1231. doi: 10.1200/JCO.1994.12.6.1223. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES